MENU
+Compare
EDIT
Stock ticker: NASDAQ
AS OF
May 23, 10:49 AM (EDT)
Price
$1.55
Change
-$0.07 (-4.32%)
Capitalization
135.61M

EDIT Editas Medicine Forecast, Technical & Fundamental Analysis

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases... Show more

Industry: #Biotechnology
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for EDIT with price predictions
May 22, 2025

EDIT's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for EDIT turned positive on May 20, 2025. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 68 cases where EDIT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on May 20, 2025. You may want to consider a long position or call options on EDIT as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

EDIT moved above its 50-day moving average on May 15, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for EDIT crossed bullishly above the 50-day moving average on May 01, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in of 240 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 119 cases where EDIT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for EDIT moved out of overbought territory on April 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EDIT broke above its upper Bollinger Band on April 22, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.172) is normal, around the industry mean (16.305). P/E Ratio (0.000) is within average values for comparable stocks, (59.561). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.188). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (3.734) is also within normal values, averaging (277.166).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

EDIT is expected to report earnings to fall 56.86% to -39 cents per share on July 30

Editas Medicine EDIT Stock Earnings Reports
Q2'25
Est.
$-0.40
Q1'25
Missed
by $0.36
Q4'24
Missed
by $0.22
Q3'24
Est.
$-0.75
Q2'24
Missed
by $0.12
The last earnings report on May 13 showed earnings per share of -92 cents, missing the estimate of -56 cents. With 46.43K shares outstanding, the current market capitalization sits at 135.61M.
A.I. Advisor
published General Information

General Information

a company which translates genome editing technology into a novel class of human therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
11 Hurley Street
Phone
+1 617 401-9000
Employees
265
Web
https://www.editasmedicine.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME30.862.81
+10.02%
GameStop Corp
TSLA341.046.42
+1.92%
Tesla
BTC.X111673.2800001995.203100
+1.82%
Bitcoin cryptocurrency
SPY583.090.23
+0.04%
SPDR® S&P 500® ETF
AAPL201.36-0.73
-0.36%
Apple

EDIT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with CRSP. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
+8.00%
CRSP - EDIT
54%
Loosely correlated
+1.46%
NTLA - EDIT
49%
Loosely correlated
+2.83%
PRME - EDIT
49%
Loosely correlated
+5.58%
ABCL - EDIT
47%
Loosely correlated
+0.50%
SLDB - EDIT
46%
Loosely correlated
+7.04%
More

Groups containing EDIT

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
+8.00%
EDIT
(4 stocks)
59%
Loosely correlated
-3.43%